0000000000143059

AUTHOR

Francesca Alt

showing 4 related works from this author

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

2017

Supplemental Digital Content is available in the text.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentT-LymphocytesEpitopes T-LymphocyteT-Cell Antigen Receptor SpecificityImmunotherapy AdoptiveEpitopeCohort StudiesExon0302 clinical medicineimmune system diseasesImmunology and AllergyMedicineProtein IsoformsChildAged 80 and overbiologyCD19CART-19B-ALLMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomaepitope-lossmedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisChild PreschoolComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleClone (B-cell biology)Gene isoformAdultAdolescentRecombinant Fusion ProteinsImmunologyAntigens CD19Receptors Antigen T-CellCancer VaccinesCD1903 medical and health sciencesYoung AdultAntigenHumansAgedPharmacologybusiness.industryInfant NewbornisoformsInfantImmunotherapy030104 developmental biologyImmunologybiology.proteinClinical StudyTumor EscapeBone marrowbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Susceptibility-weighted magnetic resonance imaging of cerebrovascular sequelae after radiotherapy for pediatric brain tumors

2017

Due to sensitive neuroimaging techniques, cerebrovascular complications such as cerebral microbleeds (CMB) and cerebral cavernous malformations (CCM) are increasingly recognized as considerable late effects after treatment for pediatric brain tumor. The aim of this study was to analyze CMB in a cohort of patients after cranial irradiation therapy for medulloblastoma or other pediatric brain tumors using susceptibility-weighted magnetic resonance imaging (SWI).Forty former pediatric brain tumor patients were enrolled in this prospective cross-sectional study and examined by cranial MRI including SWI sequences. Cerebral microbleeds, clinical symptoms and disability were evaluated.Thirty-six (…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentNeuroimagingCraniospinal IrradiationYoung Adult03 medical and health sciences0302 clinical medicineNeuroimagingmedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesChildRadiation InjuriesProspective cohort studyCerebral HemorrhageMedulloblastomamedicine.diagnostic_testBrain Neoplasmsbusiness.industryInfantMagnetic resonance imagingHematologymedicine.diseaseMagnetic Resonance ImagingRadiation therapyCross-Sectional StudiesOncologyCerebrovascular CirculationChild Preschool030220 oncology & carcinogenesisCohortDisease ProgressionFemaleRadiologyCranial IrradiationbusinessNeurocognitive030217 neurology & neurosurgeryRadiotherapy and Oncology
researchProduct

Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1

2021

Medulloblastoma is the most common malignant brain tumor in children. Immunotherapy is yet to demonstrate dramatic results in medulloblastoma, one reason being the low rate of mutations creating new antigens in this entity. In tumors with low mutational burden, gene fusions may represent a source of tumor-specific neoantigens. Here, we reviewed the landscape of fusions in medulloblastoma and analyzed their predicted immunogenicity. Furthermore, we described a new in-frame fusion protein identified by RNA-Seq. The fusion involved two genes on chromosome 2 coding for the enhancer of polycomb homolog 2 (EPC2) and GULP PTB domain containing engulfment adaptor 1 (GULP1) respectively. By qRT-PCR …

MedulloblastomafusionCancer Researchmedulloblastoma; EPC2; GULP1; fusionImmunogenicityIn silicoGULP1Neoplasms. Tumors. Oncology. Including cancer and carcinogensBiologymedulloblastomamedicine.diseaseFusion proteinEPC2OncologyAntigenCancer researchmedicineCytotoxic T cellEnhancerRC254-282CD8Cancers
researchProduct

Hemophagocytic Lymphohistiocytosis in Early Infancy- Pitfall of Differentiation between Hereditary and Infectious Reasons

2018

Abstract Hemophagocytic Lymphohistiocytosis (HLH) is characterized by pathologic immune activation which occurs either as a familial disorder or as an acquired condition. The diagnosis of HLH requires the presence of five out of nine criteria: fever, splenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis in bone marrow, hyperferritinemia, low or absent natural killer cell activity and high level of soluble interleukin-2 receptor. Here we present a 6-month-old girl with parents from Southern Italy. She suffered from hepatosplenomegaly and a recurrent high fever for 3 months' duration. On admission, she showed neurological symptoms including irritability and ne…

Hemophagocytic lymphohistiocytosisPediatricsmedicine.medical_specialtybusiness.operationbusiness.industryImmunologyHepatosplenomegalyCell BiologyHematologyFamilial Hemophagocytic Lymphohistiocytosismedicine.diseaseOctapharmaBiochemistryPancytopeniaVisceral leishmaniasisMacrophage activation syndromemedicineHemophagocytosismedicine.symptombusinessBlood
researchProduct